NFL Biosciences
ALNFL | PA
Overview
Corporate Details
- ISIN(s):
- FR0014003XO1 (+1 more)
- LEI:
- 9695006VJWNTN4UNHA27
- Country:
- France
- Address:
- 199 RUE HELENE BOUCHER, 34170 CASTELNAU-LE-LEZ
- Website:
- https://www.nflbiosciences.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Making it possible to cure smoking addiction NFL Biosciences develops a naturally based addiction withdrawal solution to help smokers willing to quit in their battle for a healthier life. NFL Biosciences is a biotechnology company pioneering innovative solutions through a breakthrough approach based on a standardized extract of tobacco leaf. NFL-101 is NFL Biosciences current core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-23 07:30 |
Capital/Financing Update
NFL Biosciences announces the success of its capital increase capped at €3 mill…
|
English | 311.5 KB | |
| 2025-05-23 07:30 |
Capital/Financing Update
Vif succès de l’augmentation de capital de NFL Biosciences avec une levée plafo…
|
French | 304.2 KB | |
| 2025-05-22 17:45 |
Capital/Financing Update
NFL Biosciences launches a capital increase of approximately €2.2 million
|
English | 354.2 KB | |
| 2025-05-22 17:45 |
Capital/Financing Update
NFL Biosciences lance une levée de fonds d’environ 2,2 millions d’euros par voi…
|
French | 310.7 KB | |
| 2025-05-21 17:45 |
Declaration of Voting Results & Voting Rights Announcements
NFL Biosciences : compte rendu de l’assemblée générale mixte du 21 mai 2025
|
French | 151.3 KB | |
| 2025-05-12 08:30 |
Regulatory News Service
NFL Biosciences strengthens its scientific committee with world-class experts t…
|
English | 177.7 KB | |
| 2025-05-12 08:30 |
Regulatory News Service
NFL Biosciences renforce son Comité Scientifique avec des experts de renommée m…
|
French | 175.8 KB | |
| 2025-05-06 18:40 |
General Meeting Notice
Assemblée générale mixte du 21 mai 2025 : modalités de mise à disposition et co…
|
French | 151.8 KB | |
| 2025-05-05 08:30 |
Regulatory News Service
NFL Biosciences announces results from a new study conducted with the CEA provi…
|
English | 352.0 KB | |
| 2025-05-05 08:30 |
Regulatory News Service
NFL Biosciences annonce les résultats d’une nouvelle étude menée avec le CEA pe…
|
French | 326.4 KB | |
| 2025-04-24 17:45 |
Regulatory News Service
Marex Group initiates coverage of NFL Biosciences with a Buy rating
|
English | 185.7 KB | |
| 2025-04-24 17:45 |
Regulatory News Service
Marex Group initie à l’achat la couverture de NFL Biosciences
|
French | 164.8 KB | |
| 2025-04-15 18:00 |
Report Publication Announcement
NFL Biosciences annonce la mise à disposition de son rapport financier annuel 2…
|
French | 179.3 KB | |
| 2025-04-11 17:45 |
Inside Information Statement
NFL Biosciences presents its 2024 annual results and provides an update on its…
|
English | 346.5 KB | |
| 2025-04-11 17:45 |
Inside Information Statement
NFL Biosciences présente ses résultats annuels 2024 et fait le point sur son pr…
|
French | 311.1 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ANIMALCARE GROUP PLC | United Kingdom | ANCR | |
|
Annexin Pharmaceuticals AB | Sweden | ANNX | |
|
Apontis Pharma AG | Germany | APPH | |
|
Aptahem AB | Sweden | APTA | |
|
Arctic Bioscience | Norway | ABS | |
|
ArcticZymes Technologies | Norway | AZT | |
|
argenx SE | Netherlands (Kingdom of the) | 1AE | |
|
ARIX BIOSCIENCE PLC | United Kingdom | ARIX | |
|
AroCell AB | Sweden | AROC | |
|
Arterra Bioscience | Italy | ABS |